TDF /博路定有效HBV，不损害肾功能

StephenW

TDF/Baraclude effective for HBV, did not impair renal function
October 21, 2015

   
HONOLULU — In a controlled study, Baraclude and tenofovir disoproxil fumarate were effective for long-term therapy among patients with chronic hepatitis B infection and did not impair renal function, according to a plenary presentation at ACG 2015.

“To the best of our knowledge, this is the first real-life cohort study that evaluated renal function by the estimation of [estimated glomerular filtration rate], phosphorus level and complete urinalysis in [chronic hepatitis B] patients under [nucleotide analogs] comparing them to a control group,” Rosa Coelho, MD, Centro Hospitalar São João, Porto, Portugal, said during her presentation.

Coelho and colleagues conducted a controlled study in a single center in Porto, Portugal, comparing renal function of three groups of patients with chronic HBV: those receiving Baraclude (entecavir, Bristol-Myers Squibb; n = 51), tenofovir disoproxil fumarate ( TDF; n = 114) and a control group of inactive carriers (n = 30).

“The renal function was assessed before and after antiviral treatment by estimated glomerular filtration rate phosphorus levels and urine sediment,” Coelho said.

The follow-up for all patients was 57 months.

Baseline estimated glomerular filtration rates (eGFR) were higher in the TDF group (84.1 ± 21.5 mL/min) and control group (82 ± 14.4 mL/min) compared with the entecavir group (73.7 ± 27.4 mL/min).

Dose reduction was needed in 16% of patients in the entecavir group and 9% of patients in the TDF group (P = .102). TDF was well-tolerated, according to Coelho; however, 4% of patients required suspension due to renal toxicity. There was no intolerance to entecavir.

The researchers observed an increase in paired eGFR in all 3 groups: entecavir (7.2 mL/min, P = .001), inactive carriers (8 mL/min, P < .001), and TDF (5.7 mL/min, P = .011).

“There were no significant changes in paired serum phosphorus levels or urinary sediment in the three groups,” Coelho said during her presentation.

The changes of eGFR and phosphorus levels were not statistically different between the groups (P = .109; P = .761), respectively.

“Long term therapy with entecavir and TDF did not result in impairment in renal function, similar to the control group, which supports long-time safety of analogue treatment for [chronic hepatitis B], providing that renal function is regularly monitored,” Coelho concluded.

Reference:

Coelho R, et al. Abstract 68. Presented at: ACG; Oct. 16-21, 2015; Honolulu.

Disclosures: The researchers report no relevant financial disclosures.

StephenW

TDF /博路定有效的HBV，不损害肾功能
2015年10月21日

   
火奴鲁鲁 - 在对照研究中，博路定和富马酸替诺福韦酯是有效的患者有慢性乙肝病毒感染的长期治疗，不损害肾功能，根据大会报告，在ACG 2015年

“对于我们所知，这是第一个现实生活中的队列研究，通过[估计肾小球滤过率]，磷水平和[慢性乙型肝炎]完整的尿检患者在[核苷酸类似物]的评估评价肾功能的比较他们对照组，“罗莎科埃略，MD，中心HOSPITALAR圣若昂，波尔图，葡萄牙，她的演讲中说。

科埃略和他的同事在葡萄牙波尔图一个单中心进行了一项对照研究，比较三组慢性HBV的肾功能：那些接受博路定（恩替卡韦，施贵宝，N = 51），富马酸替诺福韦酯（TDF; N = 114）和非活动性携带者（30例）的对照组。

“在肾功能前，抗病毒治疗通过估计肾小球滤过率磷含量及尿沉渣后评估，”科埃略说。

后续对所有患者为57个月。

基线估计的肾小球滤过率（eGFR的）是TDF组（84.1±21.5毫升/分钟），并使用恩替卡韦组（73.7±27.4毫升/分钟）相比，对照组（82±14.4毫升/分钟）的水平。

需要在患者的恩替卡韦组中16％的患者的TDF组（P = 0.102）在9％剂量减少。 TDF耐受性良好，根据科埃略;然而，4％的患者需要悬浮由于肾毒性。有没有不耐受恩替卡韦。

研究人员观察到增加配对EGFR在所有3组：恩替卡韦（7.2毫升/分钟，P = 0.001），非活动性携带者（8毫升/分钟，P <0.001），和TDF（5.7毫升/分钟，P = 0.011）。

“有成对血磷水平或在三组尿沉渣无显著的变化，”科埃略她的演讲中说。

EGFR和磷水平的变化是不是组（P = 0.109，P = 0.761）之间的显着差异，分别为。

“长期治疗恩替卡韦和TDF不导致在肾功能损伤，类似于对照组，它支持类似物治疗的长期安全性[慢性乙型肝炎]，条件是肾功能定期监测，”科埃略结束。

参考：

科埃略R等人。摘要68.提出在：ACG; 10月16日至21日，2015年;檀香山。

披露：研究人员报告没有相关财务披露。

9病成医

是说，长期使用替诺也不会导致肾功能损伤？

StephenW

回复 9病成医 的帖子

57个月随访, 9％的TDF患者需要减少剂量, 4％需要停止.

重韧

还是得观察肾功能。这个出现问题不可逆。更麻烦。

小民百姓

毕竟是药，长期要对身体没有一点副作用，似乎也不现实，只要不大就不错了

yydwch

回复 小民百姓 的帖子

只要不危害健康就行